Year in review: EmVenio in 2025
From a rebrand to clinical trial facilitation to the conference circuit, EmVenio covered a lot of ground. Here are some…
All articles by Miranda Mclaren
Miranda Mclaren
-
-
Potency assays in cell therapies: A look behind the challenges
Dr. Scott Jones has spent more than 35 years advancing assay development and currently leads BioBridge Global’s R&D department. His…
-
Clinical trial predictions and the role of technology in 2026
Looking ahead to 2026, the clinical research landscape is entering a pivotal phase. As trial design innovations, hybrid studies, and…
-
Meet the new EmVenio in 2026
Clinical research is evolving, but access to trials remains uneven. Many patients still face barriers to participation, and sponsors are…
-
Why researchers are bringing cardiovascular trials to the heart of the community
Cardiovascular disease (CVD), a broad term for conditions affecting the heart and blood vessels, remains the leading cause of death…
-
Meet the new EmVenio at OCT events across 2026
Looking towards 2026, clinical trial teams continue to face challenges surrounding recruitment and retention, while many patients continue to confront…
-
Why the industry needs to rethink its approach to IRT for smarter trials
With the role of automating patient randomisation and supply management, IRT is a critical backbone for trial execution, yet it…
-
Reducing white space in early development: Four regulatory pitfalls to avoid pre-IND
In a clinical development world divided by phases, transitions are critical at every step. The transition from nonclinical testing to…
-
How better protocol design can reduce white space in clinical development
From the start of Phase I to the completion of Phase III, the average clinical trial cycle has been increasing…
-
The resurgence of mesenchymal stem cell therapies
Dr. Zamilpa is the Executive Director of Biomanufacturing and Collaborative Programs at BBG Advanced Therapies, a subsidiary of BioBridge Global…